AMTI实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Dec 2023 @ 04:59):

Stats
今日成交量	235 210
平均成交量	320 195
市值	11.01M
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.139
ATR14	$0.0200 (7.60%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-27	Epiq Capital Group, Llc	Sell	2 149 292	Common Stock
2023-12-27	Epiq Capital Group, Llc	Sell	3 394 948	Common Stock
2023-12-27	Epiq Capital Group, Llc	Sell	2 500 000	Common Stock
2023-12-27	Epiq Capital Group, Llc	Sell	293 278	Common Stock
2023-12-27	Vandevender Aaron	Sell	212 659	Common Stock

INSIDER POWER
-68.14
Last 100 transactions
Buy: 3 477 833 \| Sell: 13 394 035

音量相关性

長: 0.02 (neutral)

短: 0.79 (moderate)

Signal:(62.898) Neutral

Applied Molecular 相关性

10 最正相关
WOOF	0.969
WKEY	0.967
JAN	0.961
NMRD	0.96
MTLS	0.958
PODD	0.957
QRTEA	0.956
STIM	0.956
GERN	0.955
ENNV	0.955

10 最负相关
IGTA	-0.965
NVCN	-0.953
OHAA	-0.952
LCA	-0.951
TIOA	-0.949
BRIVU	-0.949
FTII	-0.949
HDSN	-0.948
MSDA	-0.946
CBRG	-0.941

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Applied Molecular 相关性 - 货币/商品

0.84
( strong )

0.32
( neutral )

0.00
( neutral )

0.67
( moderate )

-0.28
( neutral )

-0.86
( strong negative )

Applied Molecular 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-3.23

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-3.23

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-4.38

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.91

Financial Reports:

No articles found.

Applied Molecular

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.